Unknown

Dataset Information

0

A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report.


ABSTRACT: The prognosis of patients with advanced urothelial carcinoma is dismal. Platinum-based chemotherapy is still the main first-line treatment for advanced urothelial carcinoma, while immunotherapy can be used as a first-line treatment option for people who cannot tolerate platinum. Immunotherapy is preferred in the second-line treatment of bladder urothelial carcinoma. PD-1 inhibitors (Pembrolizumab, nivolumab and atezolizumab) and PD-L1 inhibitors (Ddurvalumab and avelumab) have not been approved for the treatment of advanced urothelial cancer in China. We describe a patient with advanced urothelial carcinoma experienced disease progression after gemcitabine chemotherapy. Following a treatment of domestic PD-1 inhibitor (sintilimab), the patient achieved a durable complete response with mild toxicity. This case indicates that PD-1 inhibitor sintilimab might be a second-line treatment choice for advanced urothelial carcinoma.

SUBMITTER: Wang J 

PROVIDER: S-EPMC8249845 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7031824 | biostudies-literature
| S-EPMC9128378 | biostudies-literature
| S-EPMC11327133 | biostudies-literature
2017-03-01 | GSE92723 | GEO
| S-EPMC9807710 | biostudies-literature
| S-EPMC7271425 | biostudies-literature
| S-EPMC10799589 | biostudies-literature
| S-EPMC4835853 | biostudies-literature
| S-EPMC6750743 | biostudies-literature
| S-EPMC8180869 | biostudies-literature